Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15060135 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Pende M, et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24, 3112-24 15060135
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T412-p - p70S6K (mouse) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin, EGF increase
rapamycin EGF, insulin inhibit treatment-induced increase
PD184352 EGF, insulin no effect upon treatment-induced increase

T348-p - p90RSK (mouse) ▲
Orthologous residues
p90RSK (human): T359‑p, p90RSK iso3 (human): T368‑p, p90RSK (mouse): T348‑p, p90RSK iso3 (mouse): ‑, p90RSK (rat): T359‑p, p90RSK (chicken): T377‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin, EGF increase
rapamycin EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin inhibit treatment-induced increase

S352-p - p90RSK (mouse) ▲
Orthologous residues
p90RSK (human): S363‑p, p90RSK iso3 (human): S372‑p, p90RSK (mouse): S352‑p, p90RSK iso3 (mouse): ‑, p90RSK (rat): S363‑p, p90RSK (chicken): S381‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin, EGF increase
rapamycin EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin inhibit treatment-induced increase

S235-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6Kb (mouse) pharmacological activator of upstream enzyme, phospho-antibody, genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme
KINASE p70S6K (mouse) pharmacological activator of upstream enzyme, phospho-antibody, genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin, EGF increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells
PD184352 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells

S236-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6K (mouse) pharmacological activator of upstream enzyme, phospho-antibody, genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme
KINASE p70S6Kb (mouse) pharmacological activator of upstream enzyme, phospho-antibody, genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin, EGF increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells
PD184352 EGF, insulin inhibit treatment-induced increase more obvious in the S6K1-/- S6K2-/- cells

S240-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin, EGF increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin no effect upon treatment-induced increase

S244-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver, MEF (fibroblast)
 Cellular systems studied:  primary cells, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin, EGF increase
wortmannin EGF, insulin inhibit treatment-induced increase
rapamycin EGF, insulin inhibit treatment-induced increase
U0126 EGF, insulin no effect upon treatment-induced increase
PD184352 EGF, insulin no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.